About ViaCell
ViaCell is a company based in Cambridge (United States) founded in 1994 was acquired by PerkinElmer in October 2007. ViaCell has raised $63 million across 2 funding rounds from investors including DWS, PerkinElmer and Nomura. ViaCell operates in a competitive market with competitors including GenVault Corporation, iSpecimen, Indivumed, BioStorage Technologies and AminoChain, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$63 M (USD)
in 2 rounds
-
Latest Funding Round
$15 M (USD), Private Equity Round
Nov 05, 2001
-
Investors
DWS
& 3 more
-
Employee Count
Not available
-
Acquired by
PerkinElmer
(Oct 01, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ViaCell
ViaCell has successfully raised a total of $63M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $15 million completed in November 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ViaCell
ViaCell has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include DWS, PerkinElmer and Nomura.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Asset management services are offered by DWS to clients.
|
Locked | Locked | Locked | |
|
Diversified asset management services are offered globally by the firm.
|
Locked | Locked | Locked |
Investor details for ViaCell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ViaCell
Investment portfolio details for ViaCell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ViaCell
Detailed financials for ViaCell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viacell Comparisons
Peer comparison for ViaCell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ViaCell
ViaCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenVault Corporation, iSpecimen, Indivumed, BioStorage Technologies and AminoChain, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosamples are stabilized, transported, stored, and retrieved by GenVault.
|
|
| Locked | Locked | Locked |
Provider of a biorepository of human clinical specimens
|
|
| Locked | Locked | Locked |
Biospecimens are collected, preserved, and analyzed for oncology services.
|
|
| Locked | Locked | Locked |
Provides bio repository services
|
|
| Locked | Locked | Locked |
A blockchain-based platform for tokenizing and incentivizing stem cell donations
|
Detailed competitors of ViaCell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viacell
Complete news archive for ViaCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViaCell
ViaCell was founded in 1994 and raised its 1st funding round 6 years after it was founded.
ViaCell is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
ViaCell is a funded company, having raised a total of $63M across 2 funding rounds to date.
ViaCell is focused on the collection and preservation of umbilical cord blood stem cells. Its product ViaCord allows expectant families to preserve their babys umbilical cord blood at the time of birth and claims that it can be used for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. It also conducts RD to investigate potential therapeutic uses of umbilical cord blood-derived stem cells and address other maternal health needs.
ViaCell's top competitors include iSpecimen, AminoChain and GenVault Corporation.
ViaCell has 4 investors. Key investors include DWS, PerkinElmer, Nomura, and The Stephens Group.